ValiRx plc
Research ValiRx plc (VAL.L) on Bullrun: market cap GBX 178.24M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerVAL.L
- ExchangeLSE
- CountryUnited Kingdom
- SectorHealthcare
- IndustryBiotechnology
- CurrencyGBX
- Market capGBX 178.24M
- Financial periodFY2025
- RevenueGBP 31.37K
- Revenue growth-37.0%
- Net income-GBP 2.23M
- Free cash flow-GBP 1.52M
- Gross margin-19.9%
Valuation Snapshot
latest market cap is GBX 178.24M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | GBP 31.37K | -GBP 2.23M | -GBP 1.52M | -19.9% | -0.01 | GBP 791.61K | GBP 1.40K | GBP 2.86M |
| FY2024 | GBP 49.78K | -GBP 1.92M | -GBP 1.62M | -26.3% | n/a | GBP 1.56M | GBP 11.86K | GBP 4.32M |
| FY2023 | GBP 9.60K | -GBP 2.04M | -GBP 2.08M | 85.0% | -0.02 | GBP 174.68K | GBP 22.07K | GBP 3.22M |
| FY2022 | GBP 0 | -GBP 2.37M | -GBP 1.71M | n/a | -0.03 | GBP 1.14M | GBP 37.71K | GBP 4.05M |
| FY2021 | n/a | n/a | n/a | n/a | -0.02 | n/a | n/a | n/a |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-04 | GBX 178.24M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 GBX.
About ValiRx plc
ValiRx plc, together with its subsidiaries, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company develops VAL401, a reformulation of anti-psychotic drug risperidone, which completed Phase II clinical trial for the treatment of end-stage non-small cell lung cancer; VAL201, a short peptide, which completed Phase I/II clinical trial for the treatment of prostate cancer; and VAL301, a peptide, which is in pre-clinical trial for the treatment of endometriosis.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is ValiRx plc's market cap?
ValiRx plc's market capitalization is GBX 178.24M.
What does ValiRx plc do?
ValiRx plc, together with its subsidiaries, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company develops VAL401, a reformulation of anti-psychotic drug risperidone, which completed Phase II clinical trial for the treatment of end-stage non-small cell lung cancer; VAL201, a short peptide, which completed Phase I/II clinical trial for the treatment of prostate cancer; and VAL301, a peptide, which is in pre-clinical trial for the treatment of endometriosis.